Tulane University School of Medicine, 1415 Tulane Ave, New Orleans, LA, 70112, USA.
Department of Internal Medicine, Brooke Army Medical Center, San Antonio, TX, USA.
Curr Treat Options Oncol. 2021 Jan 12;22(2):15. doi: 10.1007/s11864-020-00814-z.
The treatment for metastatic renal cell carcinoma (mRCC) has significantly evolved in recent years with a deeper understanding of the molecular make-up of the disease and the clinical development of therapies with novel mechanisms of action. While some patients with more indolent disease may benefit from local therapy such as metastasectomy or cytoreductive nephrectomy, others may safely embark on an active surveillance program or be offered targeted therapy. Yet, a combination regimen including an ICI is the most effective regimen and should be considered in most mRCC cases. Ongoing studies will help determine which factors can be further used to optimize treatment selection and personalize disease management.
近年来，转移性肾细胞癌 (mRCC) 的治疗方法有了显著的发展，这得益于对疾病分子结构的更深入了解，以及新型作用机制治疗方法的临床发展。虽然一些疾病进展较缓慢的患者可能受益于局部治疗，如转移灶切除术或减瘤性肾切除术，但其他患者可能可以安全地进行主动监测或接受靶向治疗。然而，包含免疫检查点抑制剂 (ICI) 的联合治疗方案是最有效的方案，应在大多数 mRCC 病例中考虑。正在进行的研究将有助于确定哪些因素可以进一步用于优化治疗选择和实现疾病管理的个体化。
